Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07469202 2026-03-13

CYTALUX Dose Extension Study

Phase 4 Not yet recruiting

106 enrolled

GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

NCT07469488 2026-03-13

AmiCARE

Phase 4 Not yet recruiting

122 enrolled

Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Venous Thromboembolism

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4 Not yet recruiting

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06931145 2025-04-23

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Phase 4 Not yet recruiting

50 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Phase 4 Not yet recruiting

20 enrolled

Thoracic

NSCLC

NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Phase 4 Not yet recruiting

30 enrolled

Thoracic

ALK-positive Advanced NSCLC

NCT06282874 2024-02-28

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Not yet recruiting

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06276933 2024-02-26

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 4 Not yet recruiting

104 enrolled

Thoracic

Lung Neoplasms

Clinical Trials

REVIVE

CYTALUX Dose Extension Study

AmiCARE

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)